Relmada Therapeutics (RLMD) Interest Coverage Ratio (2014 - 2015)
Relmada Therapeutics (RLMD) reported Interest Coverage Ratio of 4882.52 for Q4 2015, down 22.26% year-over-year from 6280.67 in Q4 2014, and down 73.17% on a QoQ basis from 2819.49 in Q3 2015.
Relmada Therapeutics (RLMD) has 2 years of Interest Coverage Ratio data on file, last reported at 4882.52 in Q4 2015.
- Quarterly Interest Coverage Ratio fell 22.26% year-over-year to 4882.52 in Q4 2015, while the trailing twelve-month figure through Sep 2016 was 11252.96 (down 106.1% YoY) and the FY2015 annual result came in at 3474.05, changed N/A from the prior year.
- Interest Coverage Ratio eased to 4882.52 in Q4 2015 per RLMD's latest filing, from 2819.49 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 5.75 in Q1 2014 and bottomed at 36626.46 in Q1 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | -4,882.52 |
| Sep 30, 2015 | -2,819.49 |
| Jun 30, 2015 | -10,215.86 |
| Mar 31, 2015 | -36,626.46 |
| Dec 31, 2014 | -3,993.52 |
| Sep 30, 2014 | -1,139.10 |
| Jun 30, 2014 | -29.72 |
| Mar 31, 2014 | -5.75 |